Relday from Zogenix is filed at FDA for Schizophrenia

Zogenix has submitted an investigational new drug application to the FDA for Relday, which is a combination of Zogenix's DosePro needle-free, subcutaneous drug delivery system plus a proprietary, subcutaneous once-monthly formulation of risperidone for treating Schizophrenia.If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing. Zogenix believes that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to the SABER controlled-release formulation technology from Durect in combination with Zogenix's DosePro needle-free subcutaneous drug delivery system.